GREY:MDCGF - Post by User
Post by
victor16on Feb 19, 2011 10:42am
327 Views
Post# 18163573
paradigm buy rating
paradigm buy ratingFebruary 17, 2011
buy” rating and $2.50 price target. The stock finished Wednesday at 48 cents.
“We have completed a full review of Medicago’s operations and clinical data and believe the company has a tremendous opportunity to cause a structural shift in how the vaccine industry manufactures its products,” Mr. Ridgeway writes.
Medicago’s plant-based manufacturing technology is “cheaper to build, cheaper to maintain, and produces vaccines in timeframes as short as any competing technology being developed,” he added.
In addition, he said the company has generated initial data that indicates its pandemic vaccine may be “best-in-class from an efficacy standpoint, producing higher rates of immunity and cross protection against additional strains.”
https://biotuesdays.com/2011/02/17/paradigm%e2%80%99s-new-medicago-coverage-starts-with-buy/